
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Baclofen
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Allos Pharma
Deal Size : Undisclosed
Deal Type : Acquisition
Allos Pharma Acquires Global Rights to Arbaclofen and Grant Award
Details : Allos has secured worldwide rights to arbaclofen, a selective GABA-B receptor agonist previously evaluated in multiple Phase II and III trials in ASD, Fragile X syndrome and 16p11.2 deletion syndrome.
Product Name : STX209
Product Type : Miscellaneous
Upfront Cash : Undisclosed
August 21, 2025
Lead Product(s) : Baclofen
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Allos Pharma
Deal Size : Undisclosed
Deal Type : Acquisition

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Baclofen
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Allos Pharma
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Allos Pharma Secures Exclusive License on Arbaclofen in Fragile X Syndrome
Details : Arbaclofen is the active enantiomer of baclofen, a GABA-B receptor agonist. Statistically significant and clinically meaningful efficacy was observed in a prior Phase 3 trial conducted by Seaside Therapeutics in humans with Fragile X Syndrome.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
November 19, 2020
Lead Product(s) : Baclofen
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Allos Pharma
Deal Size : Undisclosed
Deal Type : Licensing Agreement

Open Label Extension Study of STX209 (Arbaclofen) in Autism Spectrum Disorders
Details : Arbaclofen is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Autism Spectrum Disorder.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 15, 2012

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Baclofen
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
An Open Label Extension Study in Subjects With Fragile X Syndrome
Details : Arbaclofen is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Fragile X Syndrome.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 15, 2012
Lead Product(s) : Baclofen
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : STX107
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study to Assess the Tolerability of a Single Dose of STX107 in Adults With Fragile X Syndrome
Details : STX107 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Fragile X Syndrome.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 30, 2011
Lead Product(s) : STX107
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Baclofen
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Arbaclofen is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Fragile X Syndrome.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 29, 2011
Lead Product(s) : Baclofen
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Details : Arbaclofen is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Autism Spectrum Disorder.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 02, 2011

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Baclofen
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Arbaclofen is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Fragile X Syndrome.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 24, 2011
Lead Product(s) : Baclofen
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Baclofen
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I
Sponsor : Joseph Gonzalez-Heydrich
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Baclofen is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Autistic Disorder.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 29, 2010
Lead Product(s) : Baclofen
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Sponsor : Joseph Gonzalez-Heydrich
Deal Size : Inapplicable
Deal Type : Inapplicable

An Open Label Extension Study of STX209 in Subjects With Autism Spectrum Disorders
Details : Arbaclofen is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Autism Spectrum Disorder.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 09, 2010
